Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Citigroup

Oric Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Citigroup raised its price target on Oric Pharmaceuticals from $16 to $17 and maintained a Buy rating, implying 118.37% upside from the stock’s price at the time of the report.
  • Analyst sentiment is broadly positive: 14 analysts rate the stock Buy, with an average rating of Moderate Buy and an average price target of $21.33.
  • Shares traded at $7.79 on Tuesday. Oric reported a quarterly loss of $0.44 per share, missing analysts’ estimate of a $0.39 loss.
  • Five stocks to consider instead of Oric Pharmaceuticals.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) had its price objective boosted by research analysts at Citigroup from $16.00 to $17.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Citigroup's price target points to a potential upside of 118.37% from the stock's current price.

Other research analysts have also recently issued research reports about the stock. HC Wainwright upped their price target on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Leerink Partners initiated coverage on shares of Oric Pharmaceuticals in a research note on Monday, October 5th. They issued an "outperform" rating and a $26.00 price objective for the company. Stifel Nicolaus raised their price target on Oric Pharmaceuticals from $14.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday, October 26th. Wedbush decreased their price objective on shares of Oric Pharmaceuticals from $17.00 to $14.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 27th. Finally, JPMorgan Chase & Co. boosted their target price on Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Wednesday, October 14th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $21.33.

Check Out Our Latest Research Report on ORIC

Oric Pharmaceuticals Stock Performance

NASDAQ:ORIC traded up $0.27 during trading on Tuesday, reaching $7.79. The company's stock had a trading volume of 158,099 shares, compared to its average volume of 1,707,004. The firm has a market cap of $806.92 million, a price-to-earnings ratio of -5.78 and a beta of 1.23. The firm has a 50 day moving average of $11.45 and a 200-day moving average of $10.99. Oric Pharmaceuticals has a 12 month low of $7.23 and a 12 month high of $14.68.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.05). Equities research analysts forecast that Oric Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 77,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00. Following the completion of the sale, the chief financial officer owned 69,828 shares in the company, valued at approximately $955,945.32. This represents a 52.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 105,000 shares of company stock worth $1,432,952. 5.70% of the stock is owned by insiders.

Institutional Trading of Oric Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Oric Pharmaceuticals during the 2nd quarter worth $73,904,000. Siren L.L.C. increased its holdings in shares of Oric Pharmaceuticals by 197.6% during the first quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock valued at $37,987,000 after acquiring an additional 1,990,617 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Oric Pharmaceuticals by 19.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company's stock worth $18,637,000 after buying an additional 244,060 shares during the period. Algert Global LLC lifted its position in Oric Pharmaceuticals by 791.3% during the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company's stock worth $13,162,000 after acquiring an additional 1,078,943 shares during the period. Finally, Braidwell LP lifted its holdings in shares of Oric Pharmaceuticals by 7.7% during the second quarter. Braidwell LP now owns 1,214,540 shares of the company's stock worth $13,153,000 after purchasing an additional 86,500 shares during the period. 95.05% of the stock is currently owned by institutional investors.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company's drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

See Also

Analyst Recommendations for Oric Pharmaceuticals (NASDAQ:ORIC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oric Pharmaceuticals Right Now?

Before you consider Oric Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.

While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines